Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non–small cell lung cancer

Background Circulating tumor DNA (ctDNA) has emerged as a noninvasive biomarker for dynamically monitoring tumors. However, published data on perioperative ctDNA in patients with operable non–small cell lung cancer (NSCLC) are currently limited. Methods This prospective study recruited 123 patients...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer 2022-02, Vol.128 (4), p.708-718
Hauptverfasser:	Li, Ning, Wang, Bao‐Xiao, Li, Jian, Shao, Yang, Li, Ming‐Tian, Li, Jian‐Jun, Kuang, Peng‐Peng, Liu, Zui, Sun, Tian‐Yu, Wu, Hui‐Qi, Ou, Wei, Wang, Si‐Yu
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomarkers Biomarkers, Tumor - blood Carcinoma, Non-Small-Cell Lung - blood Carcinoma, Non-Small-Cell Lung - surgery circulating tumor DNA (ctDNA) Circulating Tumor DNA - blood Deoxyribonucleic acid DNA Health risks Humans Lead time Lung cancer Lung Neoplasms - blood Lung Neoplasms - surgery Medical imaging Medical prognosis Metastases Minimal residual disease Monitoring Neoplasm Recurrence, Local - blood Neoplasm Recurrence, Local - pathology Non-small cell lung carcinoma non–small cell lung cancer (NSCLC) Oncology Patients Peripheral blood Prognosis Prospective Studies recurrence Risk assessment Small cell lung carcinoma Surgery Survival Telemedicine Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!